ERG 245
Alternative Names: ERG-245Latest Information Update: 28 Apr 2023
At a glance
- Originator Ergon Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action BCAT1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Cancer in USA (Intraperitoneal)
- 27 Apr 2020 Pharmacodynamics data from preclinical studies in Cancer presented at the 111th Annual Meeting of the American Association for Cancer Research (AACR-2020)
- 29 Mar 2019 Pharmacodynamics data from preclinical studies in Cancer presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)